Imperial College London
Portrait Picture

Professor Omar Usmani

Faculty of Medicine, National Heart & Lung Institute

Professor of Respiratory Medicine
 
 
 
//

Contact

 

+44 (0)20 7351 8051o.usmani

 
 
//

Location

 

Asthma LabSouth BlockRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Usmani:2021:10.1186/s12931-021-01813-w,
author = {Usmani, O and Roche, N and Wahab, E and Israel, S and Jenkins, M and Trivedi, R and Dorinsky, P and Aurivillius, M},
doi = {10.1186/s12931-021-01813-w},
journal = {Respiratory Research},
pages = {1--12},
title = {A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease},
url = {http://dx.doi.org/10.1186/s12931-021-01813-w},
volume = {22},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundTriple therapy with inhaled corticosteroids/long-acting muscarinic antagonists/long-acting β2-agonists (ICS/LAMA/LABA) is recommended for patients with chronic obstructive pulmonary disease (COPD) with continued symptoms or exacerbations, despite treatment with LAMA/LABA or ICS/LABA. The pulmonary, extrathoracic, and regional lung deposition patterns of a radiolabeled ICS/LAMA/LABA triple fixed-dose combination budesonide/glycopyrrolate/formoterol fumarate (BGF 320/18/9.6 μg), delivered via a single Aerosphere metered dose inhaler (MDI) were previously assessed in healthy volunteers and showed good deposition to the central and peripheral airways (whole lung deposition: 37.7%). Here, we report the findings assessing BGF in patients with moderate-to-very severe COPD.MethodsThis phase I, single-dose, open-label gamma scintigraphy imaging study (NCT03906045) was conducted in patients with moderate-to-very severe COPD. Patients received two actuations of BGF MDI (160/9/4.8 μg per actuation) radiolabeled with technetium99pertechnetate, not exceeding 5 MBq per actuation. Immediately following each inhalation, patients performed a breath-hold of up to 10 s, then exhaled into an exhalation filter. Gamma scintigraphy imaging of the anterior and posterior views of the lungs and stomach, and a lateral head and neck view, were performed immediately after exhalation. The primary objective of the study was to assess the pulmonary deposition of BGF. Secondary objectives assessed the deposited dose of radiolabeled BGF in the oropharyngeal and stomach regions, on the actuator, and on the exhalation filter in addition to regional airway deposition patterns in the lungs.ResultsThe mean BGF emitted dose deposited in the lungs was 32.1% (standard deviation [SD] 15.6) in patients with moderate-to-very severe COPD, 35.2% (SD 12.8) in patients with moderate COPD, and 28.7% (SD 18.4) in patients with severe/very severe COPD. Overall, the mean normalized outer/inner ra
AU  - Usmani,O
AU  - Roche,N
AU  - Wahab,E
AU  - Israel,S
AU  - Jenkins,M
AU  - Trivedi,R
AU  - Dorinsky,P
AU  - Aurivillius,M
DO  - 10.1186/s12931-021-01813-w
EP  - 12
PY  - 2021///
SN  - 1465-9921
SP  - 1
TI  - A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease
T2  - Respiratory Research
UR  - http://dx.doi.org/10.1186/s12931-021-01813-w
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000705848400002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-021-01813-w
UR  - http://hdl.handle.net/10044/1/93116
VL  - 22
ER  -
Download